Cognitive effects of pharmacotherapy for major depressive disorder: A systematic review

Journal of Clinical Psychiatry

Volumn 75, Issue 8, 2014, Pages 864-876

  Keefe, Richard S E ^a   McClintock, Shawn M ^a,c   Roth, Robert M ^d   Murali Doraiswamy, P ^a,b   Tiger, Steven ^e   Madhoo, Manisha ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e Shire Development LLC ^*  (United States)

^f SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; APOMORPHINE; ARIPIPRAZOLE; CITALOPRAM; DONEPEZIL; DULOXETINE; ESCITALOPRAM; ESTROGEN; FLUDROCORTISONE; FLUOXETINE; GALANTAMINE; KETAMINE; LISDEXAMFETAMINE; LITHIUM SALT; MINERALOCORTICOID; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; S ADENOSYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; PSYCHOTROPIC AGENT;

COGNITIVE DEFECT; DRUG EFFECT; DRUG RESPONSE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; SYSTEMATIC REVIEW; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY; DRUG COMBINATION;

ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; NEUROPSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS;

EID: 84908350036     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13r08609     Document Type: Review

References (61)

1. Marazziti D, Consoli G, Picchetti M, et al. Cognitive impairment in major depression. Eur J Pharmacol. 2010;626(l):83-86.
2. Sierksma AS, Van Den Hove DL, Steinbusch HW, et al. Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? Eur I Pharmacol. 2010;626(l):72-82.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
4. Maalouf FT, Brent D, Clark L, et al. Neurocognitive impairment in adolescent major depressive disorder: state vs trait illness markers.) Affect Disord. 2011;133(3):625-632.
5. McClintock SM, Cullum M, Husain MM, et al. Evaluation of the effects of severe depression on global cognitive function and memory. CNS Spectr. 2010;15(5):304-313.
6. Gorlyn M, Keilp J, Burke A, et al. Neurocognitive impairment in MDD is an independent component of symptom severity. Biol Psychiatry. 2012;71(suppl 1):76S.
7. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry. 2003;64(suppl 14):30-34.
8. Gualtieri CT, Johnson LG, Benedict KB. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. J Neuropsychiatry Clin Neurosci. 2006;18(2):217-225.
9. Reppermund S, Ising M, Lucae S, et al. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med. 2009;39(4):603-614.
10. ∗D: implications for clinical practice. Am J Psychiatry. 2006;163(l):28-40.
11. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180-186.
12. Alves TC, Rays J, Telles RM, et al. Effects of antidepressant treatment on cognitive performance in elderly subjects with heart failure and comorbid major depression: an exploratory study. Psychosomatics. 2007;48(l):22-30.
13. Austin MP, Mitchell P, Hadzi-Pavlovic D, et al. Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report. Psychiatry Res. 2000;97(2-3):207-215.
14. Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry. 2000;157(5):729-736.
15. Brown ES, Bobadilla L, Nejtek VA, et al. Open-label nefazodone in patients with a major depressive episode and alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):681-685.
16. Deuschle M, Kniest A, Niemann H, et al. Impaired declarative memory in depressed patients is slow to recover: clinical experience. Pharmacopsychiatry. 2004;37(4):147-151.
17. Doraiswamy PM, Krishnan KR, Oxman T, et al. Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci. 2003;58(12):M1137-MU44.
18. Farabaugh AH, Sonawalla SB, Fava M, et al. Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Hum Psychopharmacol. 2006;21(4):221-225.
19. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol. 2003;18(1):9-14.
20. Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry. 1999;7(3):221-227.
21. Gorenstein C, De Carvalho SC, Artes R, et al. Cognitive performance in depressed patients after chronic use of antidepressants. Psychopharmacology (Berl). 2006;185(l):84-92.
22. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res. 2009;43(9):855-863.
23. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry. 2000;61(8):559-568.
24. Nickel T, Sonntag A, Schill J, et al. Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol. 2003;23(2):155-168.
25. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900-909.
26. Richardson JS, Keegan DL, Bowen RC, et al. Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. Int Clin Psychopharmacol. 1994;9(l):35-40.
27. Sato S, Yamakawa Y, Terashima Y, et al. Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study. Psychiatry Clin Neurosci. 2006;60(5):584-589.
28. Spalletta G, Caltagirone C. Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. Fund Neurol. 2003;18(4):227-232.
29. Spalletta G, Ripa A, Bria P, et al. Response of emotional unawareness after stroke to antidepressant treatment. Am J Geriatr Psychiatry. 2006;14(3):220-227.
30. Wise TN, Wiltse CG, Iosifescu DV, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract. 2007;61(8):1283-1293.
31. Wroolie TE, Williams KE, Keller J, et al. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J Clin Psychopharmacol. 2006;26(4):361-366.
32. Devanand DP, Pelton GH, Marston K, et al. Sertraline treatment of elderly patients with depression and cognitive impairment. Int] Geriatr Psychiatry. 2003;18(2):123-130.
33. Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 2010;177(3):323-329.
34. Reilly JL, Lencer R, Thase ME, et al. Effects of sertraline on neurocognition in outpatients with major depressive disorder. Neuropsychopharmacology. 2011;36(suppll):S117-S118.
35. Culang-Reinlieb ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry. 2012;27(8):777-784.
36. Alev L, Altin M, Ozbek K, et al. Effect of duloxetine on functional outcomes in patients with major depressive disorder. Klinik Psikofarmakoloji Bulteni. 2011;21:S115.
37. Chang HH, Lee IH, Gean PW, et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun. 2012;26(l):90-95.
38. Hashemian F, Tabatabayi MS, Sharif JA, et al. Comparison of the effects of bupropion and fluoxetine on reaction time in adults with major depressive disorder in a 4-week, single-blind study. Klinik Psikofarmakoloji Bulteni. 2011;21:S113.
39. Katona C, Hansen T, Olsen CK. A randomised, double-blind, placebocontrolled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients. Eur Neuropsychopharmacol. 2012;22:S258-S259.
40. Murrough JW, Wan LB, Glicksberg B, et al. Ketamine and neurocognition in depression: the modulating effects of lamotrigine. Neuropsychopharmacology. 2012;38:S375.
41. Boeker H, Schulze J, Richter A, et al. Sustained cognitive impairments after clinical recovery of severe depression. J Nerv Ment Dis. 2012;200(9):773-776.
42. Culang ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry. 2009;17(10):881-888.
43. Mathew SJ, Murrough JW, Aan Het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010; l3(l):7l-82.
44. Madhoo M, Keefe RSE, Roth RM, et al. Efficacy and safety of lidexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder. Int J Neuropsychopharmacol. 2012;15(suppl):189.
45. De Battista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24(1):87-90.
46. Elgamal S, MacQueen G. Galantamine as an adjunctive treatment in major depression. J Clin Psychopharmacol. 2008;28(3):357-359.
47. Holtzheimer PE 3rd, Meeks TW, Kelley ME, et al. A double blind, placebocontrolled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry. 2008;23(6):625-631.
48. Kok RM, Vink D, Heeren TJ, et al. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry. 2007;68(8):1177-1185.
49. Morgan ML, Cook IA, Rapkin AJ, et al. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry. 2005;66(6):774-780.
50. Politis AM, Papadimitriou GN, Theleritis CG, et al. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1227-1230.
51. Reynolds CF 3rd, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. 2011;68(1):51-60.
52. Pelton GH, Harper OL, Tabert MH, et al. Randomized double-blind placebocontrolled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry. 2008;23(7):670-676.
53. Hinkelmann K, Moritz S, Botzenhardt J, et al. Changes in Cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study. Psychoneuroendocrinology. 2012;37(5):685-692.
54. Greer TL, Sunderajan P, Grannemann BD, et al. Aripiprazole augmentation improves aspects of executive function in major depressive disorder: a pilot study. Neuropsychopharmacology. 2011;36(suppl 1):S350-S351.
55. Levkovitz Y, Alpert JE, Brintz CE, et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2012;136(3):1174-1178.
56. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York, NY: Oxford University Press; 2006.
57. Barry D, Bates ME, Labouvie E. FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study. Appl Neuropsychol. 2008;15(2):97-106.
58. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301-307.
59. Snyder HR. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull. 2013;139(1):81-132.
60. Femenia T, Gomez-Galan M, Lindskog M, et al. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Res. 2012;1476:58-70.
61. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.